

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

PTO FORM 1449

ATTY. DOCKET NO.

02486.0069.NPUS01

APPLICATION NO.

10/698,066

APPLICANT

Cynthia B. Robinson, et al.

FILING DATE

October 29, 2003

GROUP

1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
UR	1.	4,254,129	Mar. 1981	Carr et al.			
	2.	4,282,233	Aug. 1981	Vilani			
	3.	4,393,066	Jul. 1983	Garrett et al.			
	4.	4,499,064	Feb. 1985	Shive			
	5.	4,525,358	Jun. 1985	Baltes et al.			
	6.	4,575,498	Mar. 1986	Holmes et al.			
	7.	4,628,052	Dec. 1986	Peat			
	8.	4,920,115	Apr. 1990	Nestler et al.			
	9.	4,931,441	Jun. 1990	Lawrence			
	10.	4,985,443	Jan. 1991	Montes			
	11.	5,021,417	Jun. 1991	Prost			
	12.	5,059,595	Oct. 1991	Le Grazie			
	13.	5,077,284	Dec. 1991	Loria et al.			
	14.	5,110,810	May 1992	Eich et al.			
	15.	5,118,505	Jun. 1992	Költringer			
	16.	5,162,198	Nov. 1992	Eich et al.			
	17.	5,173,488	Dec. 1992	Haeger			
	18.	5,177,076	Jan. 1993	Nijkerk et al.			
	19.	5,266,312	Nov. 1993	Leung et al.			
	20.	5,270,305	Dec. 1993	Palmer			
	21.	5,347,005	Sep. 1994	Mueller et al.			
	22.	5,375,693	Dec. 1994	Woosley et al.			
	23.	5,407,684	Apr. 1995	Loria et al.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT <i>(Use several sheets if necessary)</i> PTO FORM 1449	ATTY. DOCKET NO.	APPLICATION NO.
	02486.0069.NPUS01	10/698,066
	APPLICANT	
	Cynthia B. Robinson, et al.	
	FILING DATE	GROUP
	October 29, 2003	1614

U	24.	5,407,927	Apr. 1995	Morales et al.				
	25.	5,489,581	Feb. 1996	Daynes et al.				
	26.	5,527,789	Jun. 1996	Nyce				
	27.	5,532,230	Jul. 1996	Daynes et al.				
	28.	5,538,734	Jul. 1996	Le Grazie				
	29.	5,578,610	Nov. 1996	D' Ambra				
	30.	5,583,126	Dec. 1996	Daynes et al.				
	31.	5,635,496	Jun. 1997	Daynes et al.				
	32.	5,660,835	Aug. 1997	Nyce				
	33.	5,686,438	Nov. 1997	Daynes et al.				
	34.	5,703,063	Dec. 1997	Chasalow, et al.				
	35.	5,767,278	Jun. 1998	Gaeta et al.				
	36.	5,811,418	Sep. 1998	Daynes et al.				
	37.	5,859,000	Jan. 1999	Dowell et al.				
	38.	5,861,391	Jan. 1999	Yen et al.				
	39.	5,948,434	Sep. 1999	Labrie				
	40.	6,087,351	Jul. 2000	Nyce				
	41.	6,093,706	Jul. 2000	Zeligs				
	42.	2002/0042401	Apr. 2002	Ferguson et al.				
	43.	2003/0013772	Jan. 2003	Murphy et al.				
	44.	2003/0138434	Jul. 2003	Campbell et al.				
	45.	2003/0139331	Jul. 2003	Martin et al.				

Cher Blunt 7/5/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT <i>(Use several sheets if necessary)</i> PTO FORM 1449	ATTY. DOCKET NO.	APPLICATION NO.
	02486.0069.NPUS01	10/698,066
	APPLICANT Cynthia B. Robinson, et al.	
	FILED DATE	GROUP
	October 29, 2003	1614

FOREIGN PATENT DOCUMENTS								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	46. X	WO 93/16704		PCT				
	47. F	WO 96/16680		PCT				
	48. F	WO 97/48367		PCT				
	49. F	WO 98/03180		PCT				
	50. F	WO 00/54763		PCT				
	51. F	WO 01/015745		PCT				
	52. F	WO 02/069955		PCT				
	53. F	WO 02/85296		PCT				
	54. F	WO 03/072572		PCT				
	55. F	WO 04/014993 A2		PCT				
OTHER REFERENCES								
<i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>								
	56. F	Araneo et al., "Dehydroepiandrosterone Reduces Progressive Dermal Ischemia Caused by Thermal Injury", <i>J. Surg. Res.</i> 59(2):250-62 (1995).						
	57. F	Bonnett et al., "Dehydroepiandrosterone (DHEA) prevents and reverses chronic hypoxic pulmonary hypertension," <i>PNAS</i> 100(16):9488-93 (2003).						
	58. F	Budavari, The Merck Index 11 th ed., 1989, pp. 660-661, monograph 4141.						
	59. F	Coleridge et al., "Intravenous aminophylline confers no benefit in acute asthma treated with intravenous steroids and inhaled bronchodilators", <i>Aust. N.Z. J. Med.</i> 23:348-54 (1993).						
	60. X	Dashtaki et al., "Dehydroepiandrosterone and Analogs Inhibit DNA Binding of AP-1 and Airway Smooth Muscle Proliferation", <i>J. Pharmacol. Exp. Ther.</i> 285(2):876-83 (1998).						
	61. X	Dompeling et al., "Treatment with Inhaled Steroids in Asthma and Chronic Bronchitis: Long Term Compliance and Inhaler Technique", <i>Family Practice</i> 9(2):161-6 (1992).						
	62. F	Dunn, et al., "Dehydroepiandrosterone sulphate concentrations in asthmatic patients: pilot study," <i>N.Z. J. Med.</i> 97(768):805-8 (1984).						
	63. F	Duplantier, et al., Novel pharmacological approaches to the treatment of asthma: status and potential of therapeutic classes", <i>DDT</i> 1(5):199-207 (1996)						

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) PTO FORM 1449	ATTY. DOCKET NO. 02486.0069.NPUS01	APPLICATION NO. 10/698,066
	APPLICANT Cynthia B. Robinson, et al.	
	FILING DATE October 29, 2003	GROUP 1614

	64. <input checked="" type="checkbox"/>	Dworski et al., "Conspectus: Inhaled Steroids in Asthma", <i>Comprehensive Therapy</i> , 18:3 (1992).
	65. <input checked="" type="checkbox"/>	Fehér et al., "Adrenocortical Function in Bronchial Asthma", <i>Acta Medica Hungarica</i> 40(2-3):125-32 (1983).
	66. <input checked="" type="checkbox"/>	Fehér, et al., "Dehydroepiandrosterone Therapy of Patients with Corticosteroid Dependent Bronchial Asthma," <i>Natl. Institute of Rheumatism and Physiotherapy, in XIII Congress of the European Academy of Allergology and Clinical Immunology</i> , eds. (Saba, et al., Debrecen Hungary (1986).
	67. <input checked="" type="checkbox"/>	Hampl et al., "Dehydroepiandrosterone sulphate reduces chronic hypoxic pulmonary hypertension in rats," <i>J. Eur. Respir.</i> 21:862-5 (2003).
	68. <input checked="" type="checkbox"/>	Holzmann et al., "Therapy of Psoriasis with Dehydroepiandrosterone-Enanthate. II. Intramuscular Depot Application of 300 mg", <i>Arch. Dermatol. Forsch.</i> 247(1):23-8 (1973) (German with English Abstract).
	69. <input checked="" type="checkbox"/>	Hummel et al., "Comparison of oral-steroid sparing by high-dose and low-dose inhaled steroid in maintenance treatment of severe asthma", <i>The Lancet</i> , 340(8834/8835):1483-7 (1992).
	70. <input checked="" type="checkbox"/>	Itagaki et al., "Effect of Cortisol on the Release of Human Decidual", <i>Caplus</i> , 114875 (1991) (Japanese with English Abstract).
	71. <input checked="" type="checkbox"/>	Koó et al., "Our experiences with Dehydroepiandrosterone Therapy in Steroid-Dependent Intrinsic Bronchial Asthma", <i>Orvosi Hetilap</i> 128(38):1995-7 (1987) (Hungarian).
	72. <input checked="" type="checkbox"/>	Koó et al., "Our experiences with Dehydroepiandrosterone Therapy in Steroid-Dependent Intrinsic Bronchial Asthma", <i>Orvosi Hetilap</i> 128(38):1995-7 (1987) (English translation).
	73. <input checked="" type="checkbox"/>	Lejeune, "Pathogenesis of Mental Impairment in Trisomy 21", <i>Annales de Génétique</i> , 92:27643 (1996) (French with English Abstract).
	74. <input checked="" type="checkbox"/>	Mileva et al., "Androstenedione, DHEA sulfate, cortisol, aldosterone and testosterone in bronchial asthma patients", 07608054 (1990) (Russian with English Abstract).
	75. <input checked="" type="checkbox"/>	Nakagawa, et al., "The Properties of Water of Crystallization of Sodium Prasterone Sulfate," <i>Chem. Pharm. Bull</i> 29(5):1466-9 (1981)
	76. <input checked="" type="checkbox"/>	Nakagawa, et al., "The Grinding and Drying on the Solid State Stability of Sodium Prasterone Sulfate," <i>Chem. Pharm. Bull</i> 30(1):242-8 (1982)
	77. <input checked="" type="checkbox"/>	Pashko et al., "Inhibition of 7,12-dimethylbenz(a)anthracene-induced Skin Papillomas and Carcinomas by Dehydroepiandrosterone and 3-beta-methylandro-5-en-17-one in mice", <i>Cancer Res.</i> 45(1):164-6 (1985).
	78. <input checked="" type="checkbox"/>	Peeters et al., "Differences in Purine Metabolism in Patients with Down's Syndrome", <i>J. Intellect. Disabil. Res.</i> 37:471 (1993). Abstract.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT <i>(Use several sheets if necessary)</i> PTO FORM 1449	ATTY. DOCKET NO. 02486.0069.NPUS01	APPLICATION NO. 10/698,066
	APPLICANT Cynthia B. Robinson, et al.	
	FILING DATE October 29, 2003	GROUP 1614

79.	Reed, "Aerosol Steroids as Primary Treatment of Mild Asthma", <i>New England J. Med.</i> , 325(6):425-6 (1991).
80.	Rowe et al., "Effectiveness of Steroid Therapy in Acute Exacerbations of Asthma: A Meta-analysis", <i>Amer. J. Emergency Med.</i> , 10(4):301-10 (1992).
81.	Sasaki et al., "Cervical Ripening with Dehydroepiandrosterone Sulphate", <i>Br. J. Obstet. Gynaecol.</i> 89(3):195-8, (1982).
82.	Sciarra et al., "Aerosols", Remington's Pharmaceutical Sciences, 18 th ed. (1990), Eds. Gennaro et al., pp. 1873-5 and 1694-1712.
83.	Sharma et al., "Screening of potential chemopreventive agents using biochemical markers of carcinogenesis", <i>Cancer Res.</i> 54(22):5848-55 (1994).
84.	Shomali, "The Use of Anti-Aging Hormones. Melatonin. Growth Hormone, Testosterone, and Dehydroepiandrosterone: Consumer Enthusiasm for Unproven Therapies", <i>Md. Med. J.</i> 46(4):181-6 (1997).
85.	Sonka et al., "Gout and Dehydroepiandrosterone: 3. DHEA Administration", <i>Endokrynologia Polska</i> 24(3):209-18 (1973).
86.	Sur et al., "Double-blind trial pyroxidine (vitamin B6) in the treatment of steroid-dependent asthma", <i>Ann. Allergy</i> , 70:147-52 (1993).
87.	Schwartz et al., "Inhibition of 7,12-dimethylbenz[a]anthracene- and urethan-induced lung tumor formation in A/J mice by long-term treatment with dehydroepiandrosterone," <i>Carcinogenesis</i> 2(12):1335-7 (1981)
88.	Van de Graaf et al., "Respiratory Membrane Permeability and Bronchial Hyperreactivity in Patients with Stable Asthma: Effects of Therapy with Inhaled Steroids", <i>Bronchial Asthma and Respiratory Membrane Permeability</i> 143:362-8 (1991).
89.	Van Vollenhoven et al., "Dehydroepiandrosterone in SLE. Results of a Double-Blind, Placebo-Controlled, Randomized Clinical Trial.", <i>Arthritis Rheum.</i> 38(12): 1826-31 (1995).
90.	Wolkowitz et al., "Dehydroepiandrosterone Treatment of Depression", <i>Biol. Psychiatry</i> 41(3):311-8. (1997).

NOT Considered - not provided by the applicant

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[illegible][illegible]

Examiner Signature	<i>[Signature]</i>	Date Considered	6/29/2002
-----------------------	--------------------	--------------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.